SAB Biotherapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for SABS, updated each market day.
SABS AI Sentiment
AI predicts SAB Biotherapeutics, Inc. Common Stock stock is likely to increase over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About SAB Biotherapeutics, Inc. Common Stock
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses. The company's candidate, SAB-142 is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of type 1 diabetes (T1D).
Sector
Exchange
Market Cap
$269,155,984
Cap Tier
Employees
86
Headquarters
MIAMI BEACH, FL
Listed Since
Oct. 22, 2021
Website
SABS Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
SABS Volatility
SAB Biotherapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
